Implementation of gastric cancer screening - the global experience.

Gastric cancer (GC) is still an important global healthcare problem, and in absolute figures it is going to remain at the present level in foreseeable future. In general, survival of patients with GC is poor mainly due to advanced-stage diagnosis. Early-stage GC can be cured by endoscopic resection or less invasive surgical treatment. Unfortunately, there is no appropriate screening strategy available for global application. This article provides a description of established national and regional GC screening programs and the screening modalities used. This review also summarizes current approaches to develop cancer-screening biomarkers. Although candidates with initial promising results have been suggested, moving discovery into clinical practice is still a major challenge. Well-designed biomarker studies, with systematic validation steps, are needed to decrease the burden of this fatal disease.

[1]  I. Choi,et al.  Performance of gastric cancer screening by endoscopy testing through the National Cancer Screening Program of Korea , 2011, Cancer science.

[2]  P. Malfertheiner,et al.  Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED) , 2012, Endoscopy.

[3]  T. Chen,et al.  The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention , 2012, Gut.

[4]  E. Kuipers,et al.  Precancerous lesions in the stomach: from biology to clinical patient management. , 2013, Best practice & research. Clinical gastroenterology.

[5]  D. Albanes,et al.  The relationship between serum ghrelin and the risk of gastric and esophagogastric junctional adenocarcinomas. , 2011, Journal of the National Cancer Institute.

[6]  M. Pawlita,et al.  A CagA‐independent cluster of antigens related to the risk of noncardia gastric cancer: Associations between Helicobacter pylori antibodies and gastric adenocarcinoma explored by multiplex serology , 2014, International journal of cancer.

[7]  X. Shu,et al.  Prospective Study of Helicobacter pylori Biomarkers for Gastric Cancer Risk among Chinese Men , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[8]  I. Gazeley,et al.  Labour and welfare , 2015 .

[9]  Pil Je Park,et al.  Serum biomarker panels for the diagnosis of gastric adenocarcinoma , 2012, British Journal of Cancer.

[10]  Christian O. Bolz,et al.  A Novel Line Immunoassay Based on Recombinant Virulence Factors Enables Highly Specific and Sensitive Serologic Diagnosis of Helicobacter pylori Infection , 2013, Clinical and Vaccine Immunology.

[11]  K. Miki Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels — “ABC method” , 2011, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[12]  K. Mafune,et al.  The Diversity of Gastric Carcinoma , 2005 .

[13]  M. Asaka A new approach for elimination of gastric cancer deaths in Japan , 2013, International journal of cancer.

[14]  H. Haick,et al.  A nanomaterial-based breath test for distinguishing gastric cancer from benign gastric conditions , 2013, British Journal of Cancer.

[15]  P. Moayyedi,et al.  Whom should we “test and treat” for Helicobacter pylori? , 2014, BMJ : British Medical Journal.

[16]  Y. Yamaji,et al.  Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study , 2005, Gut.

[17]  K. Fock Review article: the epidemiology and prevention of gastric cancer , 2014, Alimentary pharmacology & therapeutics.

[18]  L. Kupčinskas,et al.  Value of gastrin-17 in detecting antral atrophy. , 2011, Advances in medical sciences.

[19]  S. Lo,et al.  Discovery of diagnostic serum biomarkers of gastric cancer using proteomics , 2008, Proteomics. Clinical applications.

[20]  K. Choi,et al.  The current status of gastric cancer screening in Korea: report on the National Cancer Screening Programme, 2009. , 2011, Asian Pacific journal of cancer prevention : APJCP.

[21]  M. Fujishiro,et al.  Cautious comparison between East and West is necessary in terms of the serum pepsinogen test , 2009, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society.

[22]  R. Wong,et al.  Ethnic Disparities in Gastric Cancer Incidence and Survival in the USA: An Updated Analysis of 1992–2009 SEER Data , 2014, Digestive Diseases and Sciences.

[23]  D. Morgan,et al.  Gastric cancer incidence and mortality is associated with altitude in the mountainous regions of Pacific Latin America , 2012, Cancer Causes and Control.

[24]  T. Nakajima Historical Review of Research and Treatment of Gastric Cancer in Japan: Clinical Aspect , 2005 .

[25]  M. Coleman,et al.  Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study. , 2014, The Lancet. Oncology.

[26]  Holly Janes,et al.  Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study Design , 2008, Journal of the National Cancer Institute.

[27]  C. Abnet,et al.  Interleukin-1B Polymorphisms and Gastric Cancer Risk—A Meta-analysis , 2006, Cancer Epidemiology Biomarkers & Prevention.

[28]  L. Rosero-Bixby,et al.  X-ray screening seems to reduce gastric cancer mortality by half in a community-controlled trial in Costa Rica , 2007, British Journal of Cancer.

[29]  E. Fontham,et al.  Interleukin-1β and Interleukin-1 Receptor Antagonist Gene Polymorphisms and Gastric Cancer: A Meta-analysis , 2006, Cancer Epidemiology Biomarkers & Prevention.

[30]  Wei-Chih Liao,et al.  Accuracy of faecal occult blood test and Helicobacter pylori stool antigen test for detection of upper gastrointestinal lesions , 2013, BMJ Open.

[31]  M. Asaka,et al.  Roadmap to eliminate gastric cancer with Helicobacter pylori eradication and consecutive surveillance in Japan , 2013, Journal of Gastroenterology.

[32]  H. Brenner,et al.  Gastric Parietal Cell Antibodies, Helicobacter Pylori Infection, and Chronic Atrophic Gastritis: Evidence from a Large Population-based Study in Germany , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[33]  T Rokkas,et al.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report , 2006, Gut.

[34]  N. Yoshimura,et al.  Cancer High-Risk Subjects Identified by Serum Pepsinogen Tests: Outcomes after 10-Year Follow-up in Asymptomatic Middle-Aged Males , 2008, Cancer Epidemiology Biomarkers & Prevention.

[35]  M F Dixon,et al.  Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. , 1996, The American journal of surgical pathology.

[36]  M. Leja,et al.  The effect of incisura angularis biopsy sampling on the assessment of gastritis stage , 2014, European journal of gastroenterology & hepatology.

[37]  K. Jørgensen [Cervix cancer screening]. , 2008, Ugeskrift for laeger.

[38]  J. Fraumeni,et al.  Serum pepsinogens in relation to precancerous gastric lesions in a population at high risk for gastric cancer. , 1993, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[39]  T. Chen,et al.  A Community‐Based Study of Helicobacter pylori Therapy Using the Strategy of Test, Treat, Retest, and Re‐treat Initial Treatment Failures , 2006, Helicobacter.

[40]  M. Asaka,et al.  Design and Planned Analyses of an Ongoing Randomized Trial Assessing the Preventive Effect of Helicobacter pylori Eradication on Occurrence of New Gastric Carcinomas After Endoscopic Resection , 2006, Helicobacter.

[41]  K. Choi,et al.  Cost-effectiveness outcomes of the national gastric cancer screening program in South Korea. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[42]  T. Gotoda,et al.  Detection of early gastric cancer: misunderstanding the role of mass screening , 2006, Gastric Cancer.

[43]  Jaw-Yuan Wang,et al.  Discovery of Tumor Markers for Gastric Cancer by Proteomics , 2014, PloS one.

[44]  Gian Franco Gensini,et al.  Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report , 2012, Gut.

[45]  H. Brenner,et al.  Inverse association between a pro-inflammatory genetic profile and Helicobacter pylori seropositivity among patients with chronic atrophic gastritis: enhanced elimination of the infection during disease progression? , 2009, European journal of cancer.

[46]  Tomotaka Sobue,et al.  The Japanese guidelines for gastric cancer screening. , 2008, Japanese journal of clinical oncology.

[47]  M. Pawlita,et al.  Helicobacter pylori Multiplex Serology , 2009, Helicobacter.

[48]  K. Pan,et al.  [Comparison of two gastric cancer screening schemes in a high-risk population]. , 2013, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[49]  R. Hunt,et al.  Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials , 2014, BMJ : British Medical Journal.

[50]  T. Azuma,et al.  Prescreening of a High-Risk Group for Gastric Cancer by Serologically Determined Helicobacter pylori Infection and Atrophic Gastritis , 2010, Digestive Diseases and Sciences.

[51]  H. Yatsuya,et al.  Prospective study of screening for stomach cancer in Japan , 2003, International journal of cancer.

[52]  M A Fujino,et al.  Accuracy of screening for gastric cancer using serum pepsinogen concentrations , 1999, Gut.

[53]  K. Matsuo,et al.  Genetic predisposition to Helicobacter pylori-induced gastric precancerous conditions. , 2010, World journal of gastrointestinal oncology.

[54]  E. J. Kuipers,et al.  Review article: exploring the link between Helicobacter pylori and gastric cancer , 1999, Alimentary pharmacology & therapeutics.

[55]  A. Oshima,et al.  Evaluation of a mass screening program for stomach cancer with a case‐control study design , 1986, International journal of cancer.

[56]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.

[57]  C. Mathers,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .

[58]  M. Kubo,et al.  The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study. , 2006, American journal of epidemiology.

[59]  M. Chung,et al.  The gastric fluid proteome as a potential source of gastric cancer biomarkers. , 2013, Journal of proteomics.

[60]  M. Kaminishi,et al.  Tests for serum levels of trefoil factor family proteins can improve gastric cancer screening. , 2011, Gastroenterology.

[61]  E. Kuipers,et al.  Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. , 2008, Gastroenterology.

[62]  J. Torres,et al.  Biomarkers of Helicobacter pylori-associated gastric cancer , 2013, Gut microbes.

[63]  P. Malfertheiner,et al.  Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers , 2012, Scandinavian journal of gastroenterology.

[64]  M S Pepe,et al.  Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.

[65]  S. Feig IARC Handbooks of Cancer Prevention , 2003 .

[66]  K. Ulm,et al.  Helicobacter pylori antibody responses and evolution of precancerous gastric lesions in a Chinese population , 2014, International journal of cancer.

[67]  M. Leja,et al.  Gastric cancer: prevention, screening and early diagnosis. , 2014, World journal of gastroenterology.

[68]  K. Choi,et al.  Gastric Cancer Screening in Korea: Report on the National Cancer Screening Program in 2008 , 2011, Cancer research and treatment : official journal of Korean Cancer Association.

[69]  Zhi-gang Huang,et al.  Serum trefoil factor 3 is a promising non-invasive biomarker for gastric cancer screening: A monocentric cohort study in China , 2014, BMC Gastroenterology.

[70]  Yufei Gao,et al.  Urinary metabonomics of stomach cancer assessed by rapid resolution liquid chromatography/time‐of‐flight mass spectrometry , 2013, Chinese medical journal.

[71]  P. Malfertheiner,et al.  Tumor‐associated autoantibody signature for the early detection of gastric cancer , 2013, International journal of cancer.

[72]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[73]  T. Kawamoto,et al.  Sensitivity and Specificity of Mass Screening for Gastric Cancer Using the Measurement of Serum Pepsinogens , 1995, Japanese journal of cancer research : Gann.

[74]  M. Gail,et al.  Detection of gastric carcinoma‐associated MG7‐Ag by serum immuno‐PCR assay in a high‐risk Chinese population, with implication for screening , 2010, International journal of cancer.

[75]  C. la Vecchia,et al.  Association Between Cytokine Gene Polymorphisms and Gastric Precancerous Lesions: Systematic Review and Meta-analysis , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[76]  W. Blot,et al.  Precancerous gastric lesions in a population at high risk of stomach cancer. , 1993, Cancer research.

[77]  I. Tsuji,et al.  The evaluation of screening for gastric cancer in miyagi prefecture, Japan: A population‐based case‐control study , 1995, International journal of cancer.

[78]  M. Dinis-Ribeiro,et al.  Screening for Gastric Cancer and Surveillance of Premalignant Lesions: a Systematic Review of Cost‐Effectiveness Studies , 2013, Helicobacter.

[79]  Qiaojia Huang,et al.  Identification of transgelin as a potential novel biomarker for gastric adenocarcinoma based on proteomics technology , 2008, Journal of Cancer Research and Clinical Oncology.

[80]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[81]  D. Forman,et al.  Helicobacter pylori Eradication in the Prevention of Gastric Cancer: Are More Trials Needed? , 2013, Current Oncology Reports.

[82]  L. Kupčinskas,et al.  The Validity of a Biomarker Method for Indirect Detection of Gastric Mucosal Atrophy Versus Standard Histopathology , 2009, Digestive Diseases and Sciences.

[83]  I. Lansdorp-Vogelaar,et al.  Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention. , 2013, Best practice & research. Clinical gastroenterology.

[84]  Manami Inoue,et al.  Gastric cancer screening and subsequent risk of gastric cancer: A large‐scale population‐based cohort study, with a 13‐year follow‐up in Japan , 2006, International journal of cancer.

[85]  Yoshiyuki Watanabe,et al.  Validation of the pepsinogen test method for gastric cancer screening using a follow-up study , 2009, Gastric Cancer.

[86]  P. Malfertheiner,et al.  Macro-Role of MicroRNA in Gastric Cancer , 2012, Digestive Diseases.

[87]  M. Loh,et al.  Clinical Potential of DNA Methylation in Gastric Cancer: A Meta-Analysis , 2012, PloS one.